Monthly Archives: July 2017
CAR T-Cell Therapy HCP Guide – Quality and Education: Necessary Steps
The manufacturing process for CAR-T cells is similar, even though the design and structure of the tumor specific scFv (single chain fragment variable) may...
StatPearls Question of the Week – #9
What are present hurdles faced with chimeric antigen receptor-engineered T cells (CAR-T cells) therapy?
A. Antigen loss relapse
B. On target/off tumor toxicity
C. Less efficacy...
CAR T-Cell Therapy HCP Guide – CAR Structure
In the manufacturing facility the CAR structure is synthesized using the patient's own T-cells. The CAR is a fusion protein that contains 3 distinct...
CAR T-Cell Therapy HCP Guide – Patient Delivery: The Preinfusion Conditioning Regime
Before the bioengineered T-cells are reinfused, the patient undergoes a conditioning chemotherapy regimen to reduced the competing T-cell population (lymphodepletion), lower the tumor burden...
CAR T-Cell Therapy HCP Guide – How Are CAR T-Cells Manufactured?
CAR T-cell therapy is not yet approved by the FDA and is considered investigational; a patient must enter a clinical trial to receive it....
CAR T-Cell Therapy HCP Guide – CAR T-Cell Therapy at the FDA
Axicabtagene ciloleucel (KTE-C19) from Kite Pharma was the first CAR T-cell therapy submitted to the FDA for approval in March 2017. For the current...
VIDEO: ZUMA1 trial of CD19 CAR T cells for aggressive NHL
July 6, 2017 (ecancer)
Dr Lin speaks with ecancer at EHA 2017 about clinical and biologic outcomes in patients with refractory aggressive Non-Hodgkin Lymphoma (NHL)...
Targeting immune cells that help tumors stay hidden could improve immunotherapy
June 20, 2017 (Medical News Today)
Immunotherapy drugs continue to only be effective in about 10 to 30 percent of cancer patients with certain...
New Immune Tx Achieves Remission in B-Cell Malignancies
February 16, 2016 (HealthDay News)
Patient’s T cells are engineered with chimeric antigen receptors
A new T-cell immunotherapy has led to sustained regression in many...
StatPearls Question of the Week – #8
Which condition has not been shown to respond to chimeric antigen receptor-engineered T cells (CAR-T cells) therapy?
A. Non-Hodgkin lymphoma
B. Acute lymphoblastic leukemia
C. Chronic...
